Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brainstorm Cell TherapeuticsBCLI +2.06%27 3-Year EBITDA Growth Rate is 52.90% as of Mar. 2026, which is 3969% above its 10-year median of 1.30. GuruFocus rates BCLI with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, Brainstorm Cell Therapeutics ranks better than 87.18% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 52.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 40.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 8.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Brainstorm Cell Therapeutics was 59.80% per year. The lowest was -1200.20% per year. And the median was 1.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Brainstorm Cell Therapeutics 3-Year EBITDA Growth Rate Related Terms
BCLI vs LNAI, BIVI, TOVX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Brainstorm Cell Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brainstorm Cell Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Brainstorm Cell Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 52.90% mean?
Brainstorm Cell Therapeutics (BCLI) has a 3-Year EBITDA Growth Rate of 52.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Brainstorm Cell Therapeutics and its competitors. This is 3969% above median its historical median of 1.30. According to the industry distribution chart, Brainstorm Cell Therapeutics ranks #145 out of 1131 companies in the Biotechnology industry, placing it in the top 12.8%.
Is Brainstorm Cell Therapeutics' 3-Year EBITDA Growth Rate too high?
Brainstorm Cell Therapeutics' current 3-Year EBITDA Growth Rate of 52.90% is 3969% above median its 10-year median of 1.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Brainstorm Cell Therapeutics' value of 52.90% is 255% above this industry median. Based on the distribution chart, Brainstorm Cell Therapeutics ranks #145 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' 3-Year EBITDA Growth Rate compare to LNAI and BIVI?
According to the Biotechnology industry distribution chart, Brainstorm Cell Therapeutics ranks #145 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Brainstorm Cell Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Brainstorm Cell Therapeutics' value of 52.90% is 255% above this benchmark. While the company's 10-year median is 1.30 vs. the industry median of 14.90, Brainstorm Cell Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brainstorm Cell Therapeutics's current 3-Year EBITDA Growth Rate of 52.90% is 255% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Brainstorm Cell Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brainstorm Cell Therapeutics's current 3-Year EBITDA Growth Rate is 52.90%, which is 3969% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (BCLI) has a current 3-Year EBITDA Growth Rate of 52.90%. The current 3-Year EBITDA Growth Rate is 52.90%, which is 3969% above median its 10-year median of 1.30 and 255% above the Biotechnology industry median of 14.90. Brainstorm Cell Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (BCLI), the current 3-Year EBITDA Growth Rate is 52.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
27GF Score
Get the complete analysis for BCLI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCLI has been successfully added to your 
